<VariationArchive RecordType="classified" VariationID="397516" VariationName="NC_000022.10:g.(41537227_41542742)_(41560135_41562602)dup" VariationType="Duplication" Accession="VCV000397516" Version="1" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2023-03-26" DateCreated="2017-03-27" MostRecentSubmission="2017-03-27">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="384415" VariationID="397516">
      <GeneList>
        <Gene Symbol="EP300" FullName="E1A binding protein p300" GeneID="2033" HGNC_ID="HGNC:3373" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>22q13.2</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="22" Accession="NC_000022.11" start="41092592" stop="41180077" display_start="41092592" display_stop="41180077" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="22" Accession="NC_000022.10" start="41488613" stop="41576080" display_start="41488613" display_stop="41576080" Strand="+" />
          </Location>
          <OMIM>602700</OMIM>
          <Haploinsufficiency last_evaluated="2013-03-14" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=EP300">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2013-03-14" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=EP300">No evidence available</Triplosensitivity>
        </Gene>
        <Gene Symbol="LOC126863158" FullName="BRD4-independent group 4 enhancer GRCh37_chr22:41547383-41548582" GeneID="126863158" Source="calculated" RelationshipType="genes overlapped by variant">
          <Location>
            <CytogeneticLocation>22q13.2</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="22" Accession="NC_000022.11" start="41151379" stop="41152578" display_start="41151379" display_stop="41152578" Strand="+" />
          </Location>
        </Gene>
      </GeneList>
      <Name>NC_000022.10:g.(41537227_41542742)_(41560135_41562602)dup</Name>
      <VariantType>Duplication</VariantType>
      <Location>
        <CytogeneticLocation>22q13.2</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="22" Accession="NC_000022.10" outerStart="41537227" innerStart="41542742" innerStop="41560135" outerStop="41562602" display_start="41537227" display_stop="41562602" variantLength="17394" />
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="22" Accession="NC_000022.11" outerStart="41141223" innerStart="41146738" innerStop="41164131" outerStop="41166598" display_start="41141223" display_stop="41166598" variantLength="17394" />
      </Location>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000022.10" sequenceAccession="NC_000022" sequenceVersion="10" change="g.(41537227_41542742)_(41560135_41562602)dup" Assembly="GRCh37">
            <Expression>NC_000022.10:g.(41537227_41542742)_(41560135_41562602)dup</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NC_000022.10:g.(41537227_41542742)_(41560135_41562602)dup AND Rubinstein-Taybi syndrome due to EP300 haploinsufficiency" Accession="RCV000449571" Version="1">
        <ClassifiedConditionList TraitSetID="6729">
          <ClassifiedCondition DB="MedGen" ID="C3150941">Rubinstein-Taybi syndrome due to EP300 haploinsufficiency</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2016-12-13" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2016-12-13" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2017-03-27" MostRecentSubmission="2017-03-27">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <ConditionList>
          <TraitSet ID="6729" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="15794" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Rubinstein-Taybi syndrome 2</ElementValue>
                <XRef ID="Rubinstein-Taybi+syndrome+2/9259" DB="Genetic Alliance" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Rubinstein-Taybi syndrome due to EP300 haploinsufficiency</ElementValue>
                <XRef ID="MONDO:0013364" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">RSTS2</ElementValue>
                <XRef Type="MIM" ID="613684" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">EP300</ElementValue>
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Rubinstein-Taybi syndrome (RSTS) is characterized by distinctive facial features, broad and often angulated thumbs and halluces, short stature, and moderate-to-severe intellectual disability. The characteristic craniofacial features are downslanted palpebral fissures, low-hanging columella, high palate, grimacing smile, and talon cusps. Prenatal growth is often normal, then height, weight, and head circumference percentiles rapidly drop in the first few months of life. Short stature is typical in adulthood. Obesity may develop in childhood or adolescence. Average IQ ranges between 35 and 50; however, developmental outcome varies considerably. Some individuals with EP300-RSTS have normal intellect. Additional features include ocular abnormalities, hearing loss, respiratory difficulties, congenital heart defects, renal abnormalities, cryptorchidism, feeding problems, recurrent infections, and severe constipation.</Attribute>
                <XRef ID="NBK1526" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301699</ID>
                <ID Source="BookShelf">NBK1526</ID>
              </Citation>
              <XRef ID="353284" DB="Orphanet" />
              <XRef ID="783" DB="Orphanet" />
              <XRef ID="C3150941" DB="MedGen" />
              <XRef ID="MONDO:0013364" DB="MONDO" />
              <XRef Type="MIM" ID="613684" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="1039313" SubmissionDate="2017-03-02" DateLastUpdated="2017-03-27" DateCreated="2017-03-27">
        <ClinVarSubmissionID localKey="18_March 2017|OMIM:613684" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000537705" DateUpdated="2017-03-27" DateCreated="2017-03-27" Type="SCV" Version="1" SubmitterName="Center of Genomic medicine, Geneva, University Hospital of Geneva" OrgID="505593" OrganizationCategory="laboratory" OrgAbbreviation="GenMed_GVA" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2016-12-13">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment Type="public">This the novo heterozygous tandem duplication in the EP300 gene was found in a patient with Rubinstein-Taybi syndrome.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>de novo</Origin>
              <Species TaxonomyId="9606">human</Species>
              <Age Type="minimum" age_unit="years">10</Age>
              <Age Type="maximum" age_unit="years">20</Age>
              <AffectedStatus>yes</AffectedStatus>
              <Gender>female</Gender>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="EP300" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name>p.Phe1270fs</Name>
          </OtherNameList>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000022.10:g.(41537227_41542742)_(41560135_41562602)dup</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="613684" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>Geneva_Genome_Clinic_variants_March2017</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="1039313" TraitType="Disease" MappingType="XRef" MappingValue="613684" MappingRef="OMIM">
        <MedGen CUI="C3150941" Name="Rubinstein-Taybi syndrome due to EP300 haploinsufficiency" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

